Enveric Biosciences to Participate in the H.C. Wainwright 24th Annual Global Investment Conference on September 12-14, 2022
Enveric Biosciences (NASDAQ: ENVB) announced participation in the H.C. Wainwright 24th Annual Global Investment Conference in New York City on September 12-14, 2022. President & COO Avani Kanubaddi will present on September 14 at 2:00 p.m. ET. Attendees can register here. Enveric focuses on developing innovative psychedelic-inspired medicines for mental health.
- None.
- None.
For more information about the conference, or to schedule a one-on-one meeting with Enveric’s management team, please contact your appropriate
About
Forward-Looking Statements
This press release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. These statements relate to future events or future performance. All statements other than statements of historical fact may be forward-looking statements or information. Generally, forward-looking statements and information may be identified by the use of forward-looking terminology such as “plans,”” expects” or “does not expect,” “proposed,” “is expected,” “budgets,” “scheduled,” “estimates,” “forecasts,” “intends,” “anticipates” or “does not anticipate,” or “believes,” or variations of such words and phrases, or by the use of words or phrases which state that certain actions, events or results may, could, would, or might occur or be achieved. Forward-looking statements consist of not purely historical statements, including any statements regarding beliefs, plans, expectations, or intentions regarding the future. Such forward-looking statements are based on the beliefs of management as well as assumptions made by and information currently available to management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors, including, but not limited to, the effect that the reverse stock split may have on the price of our common stock; our ability to retain our listing on the Nasdaq Capital Market; the ability of the company to successfully spin-off its cannabinoid assets; the ability to achieve the value creation contemplated by technical developments; the impact of the novel coronavirus (COVID-19) on Enveric’s ongoing and planned clinical trials; the geographic, social and economic impact of COVID-19 on Enveric’s ability to conduct its business and raise capital in the future when needed; delays in planned clinical trials; the ability to establish that potential products are efficacious or safe in preclinical or clinical trials; the ability to establish or maintain collaborations on the development of therapeutic candidates; the ability to obtain appropriate or necessary governmental approvals to market potential products; the ability to obtain future funding for developmental products and working capital and to obtain such funding on commercially reasonable terms; Enveric’s ability to manufacture product candidates on a commercial scale or in collaborations with third parties; changes in the size and nature of competitors; the ability to retain key executives and scientists; and the ability to secure and enforce legal rights related to Enveric’s products, including patent protection. A discussion of these and other factors, including risks and uncertainties with respect to Enveric, is set forth in Enveric’s filings with the
View source version on businesswire.com: https://www.businesswire.com/news/home/20220831005182/en/
Investor Contacts
212.896.1254 / 212.896.1267
EnvericBio@kcsa.com
Source:
FAQ
What is the date and time of Enveric Biosciences' presentation at the Global Investment Conference?
Where is the 24th Annual Global Investment Conference being held?
Who is presenting for Enveric Biosciences at the conference?
How can I register for the H.C. Wainwright conference to see Enveric's presentation?
What does Enveric Biosciences focus on in their drug development?
